［Abstract］　Antibody-drug conjugates(ADC) are a class of potential novel targeted drugs, with the advantages of strong selectivity of antibody and high activity of agents.In recent years,through the selection of different targets and small molecule toxic substances, coupled with the improvement of connection modes, effective ADC have been continuously developed and listed, indicating the rapid development of the personalized precision treatment. At present, three ADC have been approved for breast cancer worldwide. In addition to ado-trastuzumab emtansine(T-DM1) and trastuzumab deruxtecan(T-DXd, DS-8201) for the treatment of human epidermal growth factor receptor 2(HER2) positive breast cancer, there is also sacituzumab govitecan(SG, IMMU-132) which can benefit the patients with triple negative breast cancer(TNBC). This paper reviews the recent advances in the application of ADC for the treatment of breast cancer at home and abroad in recent years.]]> 2022/7/4 12:13:21 ZENG Cheng, ZHANG Jian 4true ［Abstract］　Human epidermal growth factor receptor 2(HER2)-positive with hormone receptor(HR)-positivebreast cancer is considered as a relatively special type of breast cancer due to its differences in molecular function, biological process, signaling pathway, clinical behavior, treatment sensitivity and intrinsic biology from other molecular subtypes of breast cancer. At present, there are many controversies and uncertainties in the selection of treatment strategies for HR-positive/HER2-positive breast cancer. How to choose a treatment strategy with better efficacy, higher safety and better accessibility is an issue that needs to be explored at present and in the future for a long time. In this paper, the relevant data of patients with HR-positive/HER2-positive breast cancer in multiple clinical studies in neoadjuvant and adjuvant therapy settings will be analyzed to find out the particularity of HR-positive/HER2-positive breast cancers, so as to provide a basis for the development of more suitable individualized treatment strategies.]]> 2022/7/4 12:13:21 LIU Bin-liang, XIE Ning, OUYANG Qu-chang 3true ［Abstract］　Over the past few decades, an improved understanding of the carcinogenicmechanism of human epidermal growth factor receptor 2(HER2) has led to the development of HER2-targeted therapies such as HER2-targeted monoclonal antibodies, tyrosine kinase inhibitors, bispecific antibodies, and antibody-drug conjugate, which are currently commonly used for HER2-positive breast cancer. Among them, the monoclonal antibody trastuzumab is the cornerstone of the current HER2-targeted therapy and its mechanism is to mediate antibody-dependent cytotoxicity(ADCC) and antibody-dependent cellular phagocytosis(ADCP) through the binding of fragment crystallizable(Fc) to Fc receptors(FcR) on the surface of immune cells after the fragment of antigen binding of the antibody recognizes the HER2 site on the surface of tumor cells. Among the FcR, Fcγ receptors(FcγR) are the main group of the FcR family. However, because of gene polymorphism of FcγR in the human body, individuals with different phenotypes have different affinities with trastuzumab. Patients with low affinity who receive the monoclonal antibody trastuzumab have poor anti-tumor effects. And by engineering its Fc fragment through glycosylation modification and amino acid mutation based on the structure of trastuzumab, the affinity and binding density between Fc and FcR can be enhanced, thereby improving the effects of ADCC and ADCP. One of the anti-HER2 monoclonal antibody magetuximab with amino acid mutation in the Fc fragment has been used in clinical practice. Furthermore, the antigen-binding fragments of monoclonal antibodies can also be further modified to recognize different HER2 epitopes or simultaneously recognize non-HER2 epitopes, which increases the density of FcγR binding sites on the surface of immune cells and then promotes ADCC.These drugs include pertuzumab and various upcoming bispecific antibodies. In this paper, the research progress of novel HER2-targeted monoclonal antibodies for breast cancer is reviewed.]]> 2022/7/4 12:13:21 ZHOU Han-xing, XU Fei 2true ［Abstract］　In recent years, targeted drugs for breast cancer have emerged one after another. However, while these drugs can improve the prognosis of cancer patients, their cardiotoxicity can not be ignored. In this paper, the pathogenesis, prevention, monitoring and intervention of cardiovascular toxicity caused by drugs related to targeted therapy of breast cancer were interpreted according to 2021 Chinese Society of Clinical Oncology(CSCO) Guidelines for the Prevention and Treatment of Cardiovascular Toxicity Related to Tumor Therapy.]]> 2022/7/4 0:00:00 ZHANG Ke-xin, FANG Feng-qi 1true